Sep 28, 2023
|
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
|
Sep 25, 2023
|
Tenapanor for Hyperphosphatemia Approved in Japan
|
Sep 11, 2023
|
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
|
Sep 8, 2023
|
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
|
Sep 7, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Aug 2, 2023
|
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
|
Jul 27, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Jul 26, 2023
|
Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
|
Jul 20, 2023
|
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
|
Jul 13, 2023
|
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
|